UNSPSC 51141595: Nafimidone hydrochloride

This classification denotes an anticonvulsant agent with the molecular formula C15H12N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LU0A7HD640, chemically known as 2-acetonaphthone, 2-(1-imidazolyl)-, hydrochloride but more generally known as nafimidone hydrochloride, which bears US NIH Compound Identifier 51199. Most nations, for tariff and trade purposes, schedule nafimidone hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, NAFIMIDONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

Nafimidone hydrochloride bears US NLM identifiers UMLS ID C2983843 and NCI Concept Code C90708. SMILES: C1CCC2CC(CCC2C1)C(=O)CN3CCNC3.CL.

UNSPSC 51141595 Nafimidone hydrochloride is a Commodity-tier code representing a single pharmaceutical product, but recent state and local solicitations tagged with this code show minimal activity directly related to nafimidone itself. Instead, the posted opportunities focus on broader pharmaceutical procurement — naloxone procurement, direct-to-manufacturer prescription programs, and multi-source generic pharmaceutical contracting — suggesting either misclassification of opportunities under this code or limited current market demand for nafimidone specifically among state and local buyers. The issuing bodies span a county health department (Seminole County, Florida), a state HHS commission (Texas), and a multi-state cooperative purchasing alliance (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, administered by the Minnesota Department of Administration). These solicitations indicate that state and local pharmaceutical procurement activity centers on emergency medical supplies, pharmacy benefit program innovation, and bulk generic pharmaceutical distribution rather than on nafimidone as a discrete procurement line item.

Geographic activity appears concentrated in the South and Upper Midwest. Seminole County, Florida's naloxone and drug deactivation systems procurement (IFB 60459723LAS, due July 26, 2023) sought annual deliveries of 1,900 units of naloxone and 800 deactivation systems with quarterly distribution to a single health facility. Texas HHS Commission's therapeutic pharmacy initiative RFI (HHS0017013, posted April 3, 2026) explored direct-to-manufacturer prescription contracting without traditional pharmacy benefit manager intermediaries. MMCAP's multi-source generic pharmaceutical RFP (S1070000015802, due March 26, 2026) recruited manufacturers to supply identified products through three authorized wholesalers across participating states including Minnesota and Oregon, with contract effectiveness July 1, 2026. The code shows little evidence of dedicated nafimidone-specific procurement activity and appears poorly aligned with actual state and local pharmaceutical buying patterns.